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LETTER TO THE EDITOR
concentration when nephrologists face uremic depres-Depression in dialysis
sion? If rubidium deficiency is confirmed, it might allow
supplementation, which could add to the tools for thepatients: Rubidium
war against uremic depression.
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E-mail: ccanavese@hotmail.comtors in dialysis patients, in which depression is carefully
reviewed [1]. Rather surprising, the participants discuss
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many data prove that a true rubidium deficiency occurs
in dialysis patients [3, 4]: (1) reduced tissue, including
Reply from the authorCNS (2250 1520 ng/g vs. 5490 1250 ng/g, P 0.0002)
Canavese et al raise the interesting notion that abnor-rubidium concentrations (Fig. 1); (2) lower serum rubid-
malities in trace elemental metabolism may be linkedium concentrations compared with normal people (304
with depression in patients treated for end-stage renal81 g/L vs. 350  74 g/L, P  0.001) with odd ratios
disease (ESRD) with hemodialysis (HD). This raisesfor rubidum 250 g/L  12.6, 95% CI 2.77 to 57.04;
points regarding the pluralistic aspects of assessing de-(3) low rubidium content (2 g/L) in solutions em-
pressive effect in patients with chronic medical illnessesployed for hemodialysis and intraperitoneal dialysis; and
[1, 2]. Rubidium plays a role in neurotransmission and(4) negative intradialytic rubidium balance (4.0  1.1
transport processes [3], as does zinc in mediating enzymemg/session).
activity and gene expression [3, 4]. Indeed, abnormalObviously, rubidium supplementation cannot modify
zinc metabolism has been linked to both inflammationthe burden of the illness, just as all the other therapeutic
options did not [1]. However, why not look for rubidium and depression in patients in both the absence of renal
Fig. 1. Rubidium concentrations in tissues of
dialysis patients () compared with normal
people ( ).
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disease [5–8] and in its presence [4]. Abnormalities in changes in meaningful and well-measured psychosocial
outcomes. Hopefully, over the next decade, we will makemineral metabolism in hemodialysis patients may impact
multiple physiologic processes that can be associated strides in identifying and understanding any relationships
that may exist between the disordered physiology ofwith decreased feelings of well-being or with neurologic
dysfunction. There are few data on the relationship be- chronic renal disease and mental disorders in our patients.
tween cellular cytokine production and circulating cyto-
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